TRUFILL N-BUTYL CYANOACRYLATE LIQUID EMBOLIC SYSTEM
Cerenovus, Inc. · Decision date Sep 25, 2000
What did the FDA approve?
FDA records P990040 as an original PMA application. The recorded decision is approval, dated Sep 25, 2000.
FDA approval order statement
APPROVAL FOR THE TRUFILL(R) N-BUTYL CYANOACRYLATE (N-BCA) LIQUID EMBOLIC SYSTEM. THE DEVICE IS INDICATED FOR THE EMBOLIZATION OF CEREBRAL ARTERIOVENOUS MALFORMATIONS (AVMS) WHEN PRESURGICAL DEVASCULARIZATION IS DESIRED.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Sep 25, 2000
Regulatory record facts
- Identifier
- P990040
- Regulatory pathway
- Premarket approval application
- Applicant
- Cerenovus, Inc.
- Product code
- KGG
- Decision code
- APPR
- Decision date
- Sep 25, 2000
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: tissue adhesive for use in embolization of brain arteriovenous malformations.
- Applicant
- Cerenovus, Inc.
- Product code
- KGG
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P990040 received
Application receipt date recorded by FDA.
P990040 · FDA decision
APPR
P990040/S037 · Related supplement
TRUFILL n-BCA Liquid Embolic System
Timeline entries are records held by MedtechLedger for P990040. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P990040
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TRUFILL n-BCA Liquid Embolic SystemP990040/S037 | Cerenovus, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cerenovus, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6303 Waterford District Dr., Suite 315, Miami, FL, 33126
Sources and methodology
- Original FDA record: P990040
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records